Related Experiment Video
Updated: Oct 6, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
Toward a Multimodal Computer-Aided Diagnostic Tool for Alzheimer's Disease Conversion
Frontiers in Neuroscience
|January 20, 2022
Summary
This study introduces an automated system to predict Alzheimer's disease (AD) conversion in mild cognitive impairment (MCI) patients using MRI and clinical data, achieving 84.7% accuracy. This tool aids primary care providers in monitoring MCI progression.
Area of Science:
- Neuroscience
- Medical Imaging
- Artificial Intelligence
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory and daily living.
- Mild cognitive impairment (MCI) patients have a high risk of progressing to AD.
- Current diagnostic methods for AD conversion rely on clinical assessment and MRI, with limited automated tools for longitudinal MCI monitoring.
Purpose of the Study:
- To develop an automated computer-assisted diagnosis (CAD) system for predicting AD conversion in MCI patients using longitudinal data.
- To address the gap in automated diagnostic tools for monitoring MCI progression in clinical settings.
- To identify key neuroimaging and clinical features associated with AD conversion.
Main Methods:
- A computationally efficient pre-processing and prediction pipeline leveraging longitudinal T1-weighted MRI, cognitive tests, and demographics.
- A convolutional neural network combining Attention and Inception architectures for pattern recognition.
- Linear registration for efficient image processing between time points.
Main Results:
- The proposed model achieved an Area Under the Curve (AUC) of 84.7% for predicting AD conversion in MCI subjects.
- This performance was significantly better than using cognitive tests and demographics alone (AUC = 80.6%).
- Key predictive features included the thalamus, caudate, planum temporale, and the Rey Auditory Verbal Learning Test.
Conclusions:
- The developed CAD system offers an objective tool for diagnosing AD conversion in MCI patients.
- The method is computationally efficient and can be integrated into clinical workflows.
- Leveraging longitudinal imaging and clinical data enhances prediction accuracy for MCI to AD progression.
Related Concept Videos
Alzheimer's Disease: Overview
719
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
719
Alzheimer's Disease: Treatment
285
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
285

